Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Cash Flow: 2016-2025

Historic Net Cash Flow for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $43.1 million.

  • Rocket Pharmaceuticals' Net Cash Flow rose 59.78% to $43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 106.47%. This contributed to the annual value of $107.7 million for FY2024, which is 227.36% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Net Cash Flow stood at $43.1 million, which was up 353.88% from -$17.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Net Cash Flow registered a high of $180.6 million during Q3 2023, and its lowest value of -$169.8 million during Q4 2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$17.0 million (2025), whereas its average is -$5.9 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Net Cash Flow plummeted by 969.48% in 2021 and then surged by 1,877.56% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$12.9 million in 2021, then tumbled by 334.02% to -$56.2 million in 2022, then slumped by 202.23% to -$169.8 million in 2023, then surged by 157.75% to $98.0 million in 2024, then surged by 59.78% to $43.1 million in 2025.
  • Its Net Cash Flow was $43.1 million in Q3 2025, compared to -$17.0 million in Q2 2025 and -$113.8 million in Q1 2025.